GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on March 2, 2021, at 8:30 a.m. ET to report its fourth quarter and year-end 2020 financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466 with participant code 1034166. A webcast replay will be available for 30 days post-call. The company focuses on developing novel glycomimetic drugs for unmet medical needs in hematology-oncology, including the evaluation of uproleselan in clinical trials.
- GlycoMimetics is developing glycomimetic drugs targeting unmet medical needs in hematology-oncology.
- Uproleselan is under evaluation in a Phase 3 trial for relapsed/refractory AML under Breakthrough Therapy Designation.
- The company has completed a Phase 1 trial for GMI-1359, a drug candidate with potential in oncology.
- None.
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.
A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1034166.
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006084/en/
FAQ
When will GlycoMimetics report its fourth quarter and year-end 2020 financial results?
How can I access the GlycoMimetics conference call?
What is the participant code for the GlycoMimetics conference call?
How long will the GlycoMimetics webcast replay be available?
